nodes	percent_of_prediction	percent_of_DWPC	metapath
Escitalopram—CYP2C19—Tamoxifen—pancreatic cancer	0.054	0.211	CbGbCtD
Escitalopram—CYP2D6—Tamoxifen—pancreatic cancer	0.0411	0.161	CbGbCtD
Escitalopram—CYP2D6—Erlotinib—pancreatic cancer	0.0349	0.136	CbGbCtD
Escitalopram—CYP3A4—Tamoxifen—pancreatic cancer	0.0261	0.102	CbGbCtD
Escitalopram—CYP3A4—Erlotinib—pancreatic cancer	0.0222	0.0868	CbGbCtD
Escitalopram—CYP3A4—Irinotecan—pancreatic cancer	0.02	0.0784	CbGbCtD
Escitalopram—CYP2D6—Doxorubicin—pancreatic cancer	0.0172	0.0673	CbGbCtD
Escitalopram—CYP3A4—Docetaxel—pancreatic cancer	0.0147	0.0574	CbGbCtD
Escitalopram—CYP3A4—Sunitinib—pancreatic cancer	0.0146	0.0572	CbGbCtD
Escitalopram—CYP3A4—Doxorubicin—pancreatic cancer	0.011	0.0428	CbGbCtD
Escitalopram—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.000147	0.000236	CcSEcCtD
Escitalopram—Diarrhoea—Irinotecan—pancreatic cancer	0.000147	0.000236	CcSEcCtD
Escitalopram—Agranulocytosis—Epirubicin—pancreatic cancer	0.000147	0.000235	CcSEcCtD
Escitalopram—Pneumonia—Doxorubicin—pancreatic cancer	0.000146	0.000234	CcSEcCtD
Escitalopram—Shock—Docetaxel—pancreatic cancer	0.000146	0.000234	CcSEcCtD
Escitalopram—Nervous system disorder—Docetaxel—pancreatic cancer	0.000146	0.000234	CcSEcCtD
Escitalopram—Pruritus—Fluorouracil—pancreatic cancer	0.000146	0.000234	CcSEcCtD
Escitalopram—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000146	0.000233	CcSEcCtD
Escitalopram—Infestation NOS—Doxorubicin—pancreatic cancer	0.000145	0.000233	CcSEcCtD
Escitalopram—Infestation—Doxorubicin—pancreatic cancer	0.000145	0.000233	CcSEcCtD
Escitalopram—Tachycardia—Docetaxel—pancreatic cancer	0.000145	0.000233	CcSEcCtD
Escitalopram—Skin disorder—Docetaxel—pancreatic cancer	0.000144	0.000231	CcSEcCtD
Escitalopram—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	0.000144	0.000231	CcSEcCtD
Escitalopram—Bradycardia—Epirubicin—pancreatic cancer	0.000144	0.00023	CcSEcCtD
Escitalopram—Diarrhoea—Gemcitabine—pancreatic cancer	0.000143	0.00023	CcSEcCtD
Escitalopram—Neuropathy peripheral—Doxorubicin—pancreatic cancer	0.000143	0.000229	CcSEcCtD
Escitalopram—Dizziness—Irinotecan—pancreatic cancer	0.000142	0.000228	CcSEcCtD
Escitalopram—Haemoglobin—Epirubicin—pancreatic cancer	0.000142	0.000227	CcSEcCtD
Escitalopram—Jaundice—Doxorubicin—pancreatic cancer	0.000142	0.000227	CcSEcCtD
Escitalopram—Stomatitis—Doxorubicin—pancreatic cancer	0.000142	0.000227	CcSEcCtD
Escitalopram—Anorexia—Docetaxel—pancreatic cancer	0.000142	0.000227	CcSEcCtD
Escitalopram—Rhinitis—Epirubicin—pancreatic cancer	0.000141	0.000227	CcSEcCtD
Escitalopram—Conjunctivitis—Doxorubicin—pancreatic cancer	0.000141	0.000227	CcSEcCtD
Escitalopram—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000141	0.000227	CcSEcCtD
Escitalopram—Haemorrhage—Epirubicin—pancreatic cancer	0.000141	0.000226	CcSEcCtD
Escitalopram—Hepatitis—Epirubicin—pancreatic cancer	0.000141	0.000226	CcSEcCtD
Escitalopram—Diarrhoea—Fluorouracil—pancreatic cancer	0.000141	0.000226	CcSEcCtD
Escitalopram—Hypoaesthesia—Epirubicin—pancreatic cancer	0.00014	0.000225	CcSEcCtD
Escitalopram—Pharyngitis—Epirubicin—pancreatic cancer	0.00014	0.000224	CcSEcCtD
Escitalopram—Sweating—Doxorubicin—pancreatic cancer	0.000139	0.000224	CcSEcCtD
Escitalopram—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000139	0.000223	CcSEcCtD
Escitalopram—Oedema peripheral—Epirubicin—pancreatic cancer	0.000139	0.000223	CcSEcCtD
Escitalopram—Hypotension—Docetaxel—pancreatic cancer	0.000139	0.000223	CcSEcCtD
Escitalopram—Haematuria—Doxorubicin—pancreatic cancer	0.000139	0.000222	CcSEcCtD
Escitalopram—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000139	0.000222	CcSEcCtD
Escitalopram—Urethral disorder—Epirubicin—pancreatic cancer	0.000138	0.000222	CcSEcCtD
Escitalopram—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.000138	0.00022	CcSEcCtD
Escitalopram—Epistaxis—Doxorubicin—pancreatic cancer	0.000137	0.00022	CcSEcCtD
Escitalopram—Vomiting—Irinotecan—pancreatic cancer	0.000137	0.000219	CcSEcCtD
Escitalopram—Sinusitis—Doxorubicin—pancreatic cancer	0.000136	0.000219	CcSEcCtD
Escitalopram—Dizziness—Fluorouracil—pancreatic cancer	0.000136	0.000218	CcSEcCtD
Escitalopram—Visual impairment—Epirubicin—pancreatic cancer	0.000136	0.000218	CcSEcCtD
Escitalopram—Agranulocytosis—Doxorubicin—pancreatic cancer	0.000136	0.000218	CcSEcCtD
Escitalopram—Rash—Irinotecan—pancreatic cancer	0.000136	0.000217	CcSEcCtD
Escitalopram—Dermatitis—Irinotecan—pancreatic cancer	0.000135	0.000217	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000135	0.000217	CcSEcCtD
Escitalopram—Headache—Irinotecan—pancreatic cancer	0.000135	0.000216	CcSEcCtD
Escitalopram—Insomnia—Docetaxel—pancreatic cancer	0.000134	0.000215	CcSEcCtD
Escitalopram—Paraesthesia—Docetaxel—pancreatic cancer	0.000133	0.000214	CcSEcCtD
Escitalopram—Erythema multiforme—Epirubicin—pancreatic cancer	0.000133	0.000214	CcSEcCtD
Escitalopram—Vomiting—Gemcitabine—pancreatic cancer	0.000133	0.000213	CcSEcCtD
Escitalopram—Bradycardia—Doxorubicin—pancreatic cancer	0.000133	0.000213	CcSEcCtD
Escitalopram—Dyspnoea—Docetaxel—pancreatic cancer	0.000133	0.000212	CcSEcCtD
Escitalopram—Somnolence—Docetaxel—pancreatic cancer	0.000132	0.000212	CcSEcCtD
Escitalopram—Rash—Gemcitabine—pancreatic cancer	0.000132	0.000212	CcSEcCtD
Escitalopram—Dermatitis—Gemcitabine—pancreatic cancer	0.000132	0.000211	CcSEcCtD
Escitalopram—Eye disorder—Epirubicin—pancreatic cancer	0.000132	0.000211	CcSEcCtD
Escitalopram—Tinnitus—Epirubicin—pancreatic cancer	0.000132	0.000211	CcSEcCtD
Escitalopram—Haemoglobin—Doxorubicin—pancreatic cancer	0.000131	0.00021	CcSEcCtD
Escitalopram—Headache—Gemcitabine—pancreatic cancer	0.000131	0.00021	CcSEcCtD
Escitalopram—Cardiac disorder—Epirubicin—pancreatic cancer	0.000131	0.00021	CcSEcCtD
Escitalopram—Flushing—Epirubicin—pancreatic cancer	0.000131	0.00021	CcSEcCtD
Escitalopram—Vomiting—Fluorouracil—pancreatic cancer	0.000131	0.00021	CcSEcCtD
Escitalopram—Rhinitis—Doxorubicin—pancreatic cancer	0.000131	0.00021	CcSEcCtD
Escitalopram—Dyspepsia—Docetaxel—pancreatic cancer	0.000131	0.00021	CcSEcCtD
Escitalopram—Hepatitis—Doxorubicin—pancreatic cancer	0.000131	0.000209	CcSEcCtD
Escitalopram—Haemorrhage—Doxorubicin—pancreatic cancer	0.000131	0.000209	CcSEcCtD
Escitalopram—Hypoaesthesia—Doxorubicin—pancreatic cancer	0.00013	0.000208	CcSEcCtD
Escitalopram—Rash—Fluorouracil—pancreatic cancer	0.00013	0.000208	CcSEcCtD
Escitalopram—Dermatitis—Fluorouracil—pancreatic cancer	0.00013	0.000208	CcSEcCtD
Escitalopram—Pharyngitis—Doxorubicin—pancreatic cancer	0.00013	0.000208	CcSEcCtD
Escitalopram—Decreased appetite—Docetaxel—pancreatic cancer	0.000129	0.000207	CcSEcCtD
Escitalopram—Headache—Fluorouracil—pancreatic cancer	0.000129	0.000207	CcSEcCtD
Escitalopram—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000129	0.000207	CcSEcCtD
Escitalopram—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000129	0.000206	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000128	0.000206	CcSEcCtD
Escitalopram—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000128	0.000206	CcSEcCtD
Escitalopram—Fatigue—Docetaxel—pancreatic cancer	0.000128	0.000205	CcSEcCtD
Escitalopram—Angiopathy—Epirubicin—pancreatic cancer	0.000128	0.000205	CcSEcCtD
Escitalopram—Urethral disorder—Doxorubicin—pancreatic cancer	0.000128	0.000205	CcSEcCtD
Escitalopram—Nausea—Irinotecan—pancreatic cancer	0.000128	0.000205	CcSEcCtD
Escitalopram—Immune system disorder—Epirubicin—pancreatic cancer	0.000127	0.000204	CcSEcCtD
Escitalopram—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000127	0.000204	CcSEcCtD
Escitalopram—Constipation—Docetaxel—pancreatic cancer	0.000127	0.000204	CcSEcCtD
Escitalopram—Pain—Docetaxel—pancreatic cancer	0.000127	0.000204	CcSEcCtD
Escitalopram—Chills—Epirubicin—pancreatic cancer	0.000127	0.000203	CcSEcCtD
Escitalopram—Arrhythmia—Epirubicin—pancreatic cancer	0.000126	0.000202	CcSEcCtD
Escitalopram—Visual impairment—Doxorubicin—pancreatic cancer	0.000126	0.000202	CcSEcCtD
Escitalopram—Alopecia—Epirubicin—pancreatic cancer	0.000125	0.0002	CcSEcCtD
Escitalopram—Nausea—Gemcitabine—pancreatic cancer	0.000124	0.000199	CcSEcCtD
Escitalopram—Mental disorder—Epirubicin—pancreatic cancer	0.000124	0.000198	CcSEcCtD
Escitalopram—Erythema multiforme—Doxorubicin—pancreatic cancer	0.000123	0.000198	CcSEcCtD
Escitalopram—Erythema—Epirubicin—pancreatic cancer	0.000123	0.000197	CcSEcCtD
Escitalopram—Malnutrition—Epirubicin—pancreatic cancer	0.000123	0.000197	CcSEcCtD
Escitalopram—Feeling abnormal—Docetaxel—pancreatic cancer	0.000122	0.000196	CcSEcCtD
Escitalopram—Nausea—Fluorouracil—pancreatic cancer	0.000122	0.000196	CcSEcCtD
Escitalopram—Eye disorder—Doxorubicin—pancreatic cancer	0.000122	0.000196	CcSEcCtD
Escitalopram—Tinnitus—Doxorubicin—pancreatic cancer	0.000122	0.000195	CcSEcCtD
Escitalopram—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000122	0.000195	CcSEcCtD
Escitalopram—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000121	0.000194	CcSEcCtD
Escitalopram—Flushing—Doxorubicin—pancreatic cancer	0.000121	0.000194	CcSEcCtD
Escitalopram—Flatulence—Epirubicin—pancreatic cancer	0.000121	0.000194	CcSEcCtD
Escitalopram—Tension—Epirubicin—pancreatic cancer	0.000121	0.000193	CcSEcCtD
Escitalopram—Dysgeusia—Epirubicin—pancreatic cancer	0.00012	0.000193	CcSEcCtD
Escitalopram—Nervousness—Epirubicin—pancreatic cancer	0.000119	0.000191	CcSEcCtD
Escitalopram—Back pain—Epirubicin—pancreatic cancer	0.000119	0.00019	CcSEcCtD
Escitalopram—Angiopathy—Doxorubicin—pancreatic cancer	0.000118	0.00019	CcSEcCtD
Escitalopram—Muscle spasms—Epirubicin—pancreatic cancer	0.000118	0.000189	CcSEcCtD
Escitalopram—Immune system disorder—Doxorubicin—pancreatic cancer	0.000118	0.000189	CcSEcCtD
Escitalopram—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000118	0.000189	CcSEcCtD
Escitalopram—Body temperature increased—Docetaxel—pancreatic cancer	0.000117	0.000188	CcSEcCtD
Escitalopram—Abdominal pain—Docetaxel—pancreatic cancer	0.000117	0.000188	CcSEcCtD
Escitalopram—Chills—Doxorubicin—pancreatic cancer	0.000117	0.000188	CcSEcCtD
Escitalopram—Arrhythmia—Doxorubicin—pancreatic cancer	0.000117	0.000187	CcSEcCtD
Escitalopram—Vision blurred—Epirubicin—pancreatic cancer	0.000116	0.000186	CcSEcCtD
Escitalopram—Alopecia—Doxorubicin—pancreatic cancer	0.000115	0.000185	CcSEcCtD
Escitalopram—Mental disorder—Doxorubicin—pancreatic cancer	0.000114	0.000183	CcSEcCtD
Escitalopram—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000114	0.000183	CcSEcCtD
Escitalopram—Erythema—Doxorubicin—pancreatic cancer	0.000114	0.000182	CcSEcCtD
Escitalopram—Malnutrition—Doxorubicin—pancreatic cancer	0.000114	0.000182	CcSEcCtD
Escitalopram—Anaemia—Epirubicin—pancreatic cancer	0.000114	0.000182	CcSEcCtD
Escitalopram—Agitation—Epirubicin—pancreatic cancer	0.000113	0.000181	CcSEcCtD
Escitalopram—Flatulence—Doxorubicin—pancreatic cancer	0.000112	0.00018	CcSEcCtD
Escitalopram—Tension—Doxorubicin—pancreatic cancer	0.000112	0.000179	CcSEcCtD
Escitalopram—Dysgeusia—Doxorubicin—pancreatic cancer	0.000111	0.000178	CcSEcCtD
Escitalopram—Malaise—Epirubicin—pancreatic cancer	0.000111	0.000178	CcSEcCtD
Escitalopram—Nervousness—Doxorubicin—pancreatic cancer	0.00011	0.000177	CcSEcCtD
Escitalopram—Vertigo—Epirubicin—pancreatic cancer	0.00011	0.000177	CcSEcCtD
Escitalopram—Syncope—Epirubicin—pancreatic cancer	0.00011	0.000177	CcSEcCtD
Escitalopram—Leukopenia—Epirubicin—pancreatic cancer	0.00011	0.000176	CcSEcCtD
Escitalopram—Back pain—Doxorubicin—pancreatic cancer	0.00011	0.000176	CcSEcCtD
Escitalopram—Hypersensitivity—Docetaxel—pancreatic cancer	0.00011	0.000176	CcSEcCtD
Escitalopram—Muscle spasms—Doxorubicin—pancreatic cancer	0.000109	0.000175	CcSEcCtD
Escitalopram—Palpitations—Epirubicin—pancreatic cancer	0.000109	0.000174	CcSEcCtD
Escitalopram—Loss of consciousness—Epirubicin—pancreatic cancer	0.000108	0.000173	CcSEcCtD
Escitalopram—Cough—Epirubicin—pancreatic cancer	0.000107	0.000172	CcSEcCtD
Escitalopram—Vision blurred—Doxorubicin—pancreatic cancer	0.000107	0.000172	CcSEcCtD
Escitalopram—Asthenia—Docetaxel—pancreatic cancer	0.000107	0.000171	CcSEcCtD
Escitalopram—Convulsion—Epirubicin—pancreatic cancer	0.000106	0.000171	CcSEcCtD
Escitalopram—Hypertension—Epirubicin—pancreatic cancer	0.000106	0.00017	CcSEcCtD
Escitalopram—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000105	0.000169	CcSEcCtD
Escitalopram—Pruritus—Docetaxel—pancreatic cancer	0.000105	0.000169	CcSEcCtD
Escitalopram—Anaemia—Doxorubicin—pancreatic cancer	0.000105	0.000168	CcSEcCtD
Escitalopram—Arthralgia—Epirubicin—pancreatic cancer	0.000105	0.000168	CcSEcCtD
Escitalopram—Myalgia—Epirubicin—pancreatic cancer	0.000105	0.000168	CcSEcCtD
Escitalopram—Chest pain—Epirubicin—pancreatic cancer	0.000105	0.000168	CcSEcCtD
Escitalopram—Agitation—Doxorubicin—pancreatic cancer	0.000104	0.000167	CcSEcCtD
Escitalopram—Anxiety—Epirubicin—pancreatic cancer	0.000104	0.000167	CcSEcCtD
Escitalopram—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000104	0.000166	CcSEcCtD
Escitalopram—Discomfort—Epirubicin—pancreatic cancer	0.000103	0.000166	CcSEcCtD
Escitalopram—Malaise—Doxorubicin—pancreatic cancer	0.000102	0.000164	CcSEcCtD
Escitalopram—Dry mouth—Epirubicin—pancreatic cancer	0.000102	0.000164	CcSEcCtD
Escitalopram—Vertigo—Doxorubicin—pancreatic cancer	0.000102	0.000164	CcSEcCtD
Escitalopram—Syncope—Doxorubicin—pancreatic cancer	0.000102	0.000163	CcSEcCtD
Escitalopram—Leukopenia—Doxorubicin—pancreatic cancer	0.000102	0.000163	CcSEcCtD
Escitalopram—Diarrhoea—Docetaxel—pancreatic cancer	0.000102	0.000163	CcSEcCtD
Escitalopram—Confusional state—Epirubicin—pancreatic cancer	0.000101	0.000162	CcSEcCtD
Escitalopram—Palpitations—Doxorubicin—pancreatic cancer	0.0001	0.000161	CcSEcCtD
Escitalopram—Anaphylactic shock—Epirubicin—pancreatic cancer	0.0001	0.000161	CcSEcCtD
Escitalopram—Oedema—Epirubicin—pancreatic cancer	0.0001	0.000161	CcSEcCtD
Escitalopram—Loss of consciousness—Doxorubicin—pancreatic cancer	9.99e-05	0.00016	CcSEcCtD
Escitalopram—Infection—Epirubicin—pancreatic cancer	9.96e-05	0.00016	CcSEcCtD
Escitalopram—Cough—Doxorubicin—pancreatic cancer	9.92e-05	0.000159	CcSEcCtD
Escitalopram—Shock—Epirubicin—pancreatic cancer	9.86e-05	0.000158	CcSEcCtD
Escitalopram—Convulsion—Doxorubicin—pancreatic cancer	9.85e-05	0.000158	CcSEcCtD
Escitalopram—Nervous system disorder—Epirubicin—pancreatic cancer	9.83e-05	0.000158	CcSEcCtD
Escitalopram—Dizziness—Docetaxel—pancreatic cancer	9.83e-05	0.000158	CcSEcCtD
Escitalopram—Thrombocytopenia—Epirubicin—pancreatic cancer	9.82e-05	0.000157	CcSEcCtD
Escitalopram—Hypertension—Doxorubicin—pancreatic cancer	9.81e-05	0.000157	CcSEcCtD
Escitalopram—Tachycardia—Epirubicin—pancreatic cancer	9.78e-05	0.000157	CcSEcCtD
Escitalopram—Skin disorder—Epirubicin—pancreatic cancer	9.74e-05	0.000156	CcSEcCtD
Escitalopram—Hyperhidrosis—Epirubicin—pancreatic cancer	9.69e-05	0.000155	CcSEcCtD
Escitalopram—Arthralgia—Doxorubicin—pancreatic cancer	9.68e-05	0.000155	CcSEcCtD
Escitalopram—Myalgia—Doxorubicin—pancreatic cancer	9.68e-05	0.000155	CcSEcCtD
Escitalopram—Chest pain—Doxorubicin—pancreatic cancer	9.68e-05	0.000155	CcSEcCtD
Escitalopram—Anxiety—Doxorubicin—pancreatic cancer	9.64e-05	0.000155	CcSEcCtD
Escitalopram—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	9.61e-05	0.000154	CcSEcCtD
Escitalopram—Discomfort—Doxorubicin—pancreatic cancer	9.56e-05	0.000153	CcSEcCtD
Escitalopram—Anorexia—Epirubicin—pancreatic cancer	9.56e-05	0.000153	CcSEcCtD
Escitalopram—Dry mouth—Doxorubicin—pancreatic cancer	9.46e-05	0.000152	CcSEcCtD
Escitalopram—Vomiting—Docetaxel—pancreatic cancer	9.45e-05	0.000151	CcSEcCtD
Escitalopram—Rash—Docetaxel—pancreatic cancer	9.37e-05	0.00015	CcSEcCtD
Escitalopram—Hypotension—Epirubicin—pancreatic cancer	9.37e-05	0.00015	CcSEcCtD
Escitalopram—Dermatitis—Docetaxel—pancreatic cancer	9.36e-05	0.00015	CcSEcCtD
Escitalopram—Confusional state—Doxorubicin—pancreatic cancer	9.35e-05	0.00015	CcSEcCtD
Escitalopram—Headache—Docetaxel—pancreatic cancer	9.31e-05	0.000149	CcSEcCtD
Escitalopram—Anaphylactic shock—Doxorubicin—pancreatic cancer	9.28e-05	0.000149	CcSEcCtD
Escitalopram—Oedema—Doxorubicin—pancreatic cancer	9.28e-05	0.000149	CcSEcCtD
Escitalopram—Infection—Doxorubicin—pancreatic cancer	9.22e-05	0.000148	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	9.13e-05	0.000146	CcSEcCtD
Escitalopram—Shock—Doxorubicin—pancreatic cancer	9.13e-05	0.000146	CcSEcCtD
Escitalopram—Nervous system disorder—Doxorubicin—pancreatic cancer	9.1e-05	0.000146	CcSEcCtD
Escitalopram—Thrombocytopenia—Doxorubicin—pancreatic cancer	9.08e-05	0.000146	CcSEcCtD
Escitalopram—Insomnia—Epirubicin—pancreatic cancer	9.07e-05	0.000145	CcSEcCtD
Escitalopram—Tachycardia—Doxorubicin—pancreatic cancer	9.05e-05	0.000145	CcSEcCtD
Escitalopram—Skin disorder—Doxorubicin—pancreatic cancer	9.01e-05	0.000144	CcSEcCtD
Escitalopram—Paraesthesia—Epirubicin—pancreatic cancer	9e-05	0.000144	CcSEcCtD
Escitalopram—Hyperhidrosis—Doxorubicin—pancreatic cancer	8.97e-05	0.000144	CcSEcCtD
Escitalopram—Dyspnoea—Epirubicin—pancreatic cancer	8.94e-05	0.000143	CcSEcCtD
Escitalopram—Somnolence—Epirubicin—pancreatic cancer	8.91e-05	0.000143	CcSEcCtD
Escitalopram—Anorexia—Doxorubicin—pancreatic cancer	8.84e-05	0.000142	CcSEcCtD
Escitalopram—Nausea—Docetaxel—pancreatic cancer	8.83e-05	0.000142	CcSEcCtD
Escitalopram—Dyspepsia—Epirubicin—pancreatic cancer	8.82e-05	0.000141	CcSEcCtD
Escitalopram—Decreased appetite—Epirubicin—pancreatic cancer	8.72e-05	0.00014	CcSEcCtD
Escitalopram—Hypotension—Doxorubicin—pancreatic cancer	8.67e-05	0.000139	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Epirubicin—pancreatic cancer	8.66e-05	0.000139	CcSEcCtD
Escitalopram—Fatigue—Epirubicin—pancreatic cancer	8.64e-05	0.000139	CcSEcCtD
Escitalopram—Pain—Epirubicin—pancreatic cancer	8.57e-05	0.000137	CcSEcCtD
Escitalopram—Constipation—Epirubicin—pancreatic cancer	8.57e-05	0.000137	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	8.45e-05	0.000135	CcSEcCtD
Escitalopram—Insomnia—Doxorubicin—pancreatic cancer	8.39e-05	0.000134	CcSEcCtD
Escitalopram—Paraesthesia—Doxorubicin—pancreatic cancer	8.33e-05	0.000134	CcSEcCtD
Escitalopram—Dyspnoea—Doxorubicin—pancreatic cancer	8.27e-05	0.000133	CcSEcCtD
Escitalopram—Feeling abnormal—Epirubicin—pancreatic cancer	8.26e-05	0.000132	CcSEcCtD
Escitalopram—Somnolence—Doxorubicin—pancreatic cancer	8.25e-05	0.000132	CcSEcCtD
Escitalopram—Gastrointestinal pain—Epirubicin—pancreatic cancer	8.2e-05	0.000131	CcSEcCtD
Escitalopram—Dyspepsia—Doxorubicin—pancreatic cancer	8.17e-05	0.000131	CcSEcCtD
Escitalopram—Decreased appetite—Doxorubicin—pancreatic cancer	8.06e-05	0.000129	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	8.01e-05	0.000128	CcSEcCtD
Escitalopram—Fatigue—Doxorubicin—pancreatic cancer	8e-05	0.000128	CcSEcCtD
Escitalopram—Urticaria—Epirubicin—pancreatic cancer	7.96e-05	0.000128	CcSEcCtD
Escitalopram—Pain—Doxorubicin—pancreatic cancer	7.93e-05	0.000127	CcSEcCtD
Escitalopram—Constipation—Doxorubicin—pancreatic cancer	7.93e-05	0.000127	CcSEcCtD
Escitalopram—Body temperature increased—Epirubicin—pancreatic cancer	7.93e-05	0.000127	CcSEcCtD
Escitalopram—Abdominal pain—Epirubicin—pancreatic cancer	7.93e-05	0.000127	CcSEcCtD
Escitalopram—Feeling abnormal—Doxorubicin—pancreatic cancer	7.64e-05	0.000123	CcSEcCtD
Escitalopram—Gastrointestinal pain—Doxorubicin—pancreatic cancer	7.59e-05	0.000122	CcSEcCtD
Escitalopram—Hypersensitivity—Epirubicin—pancreatic cancer	7.39e-05	0.000118	CcSEcCtD
Escitalopram—Urticaria—Doxorubicin—pancreatic cancer	7.37e-05	0.000118	CcSEcCtD
Escitalopram—Abdominal pain—Doxorubicin—pancreatic cancer	7.33e-05	0.000118	CcSEcCtD
Escitalopram—Body temperature increased—Doxorubicin—pancreatic cancer	7.33e-05	0.000118	CcSEcCtD
Escitalopram—Asthenia—Epirubicin—pancreatic cancer	7.19e-05	0.000115	CcSEcCtD
Escitalopram—Pruritus—Epirubicin—pancreatic cancer	7.09e-05	0.000114	CcSEcCtD
Escitalopram—Diarrhoea—Epirubicin—pancreatic cancer	6.86e-05	0.00011	CcSEcCtD
Escitalopram—Hypersensitivity—Doxorubicin—pancreatic cancer	6.83e-05	0.00011	CcSEcCtD
Escitalopram—Asthenia—Doxorubicin—pancreatic cancer	6.66e-05	0.000107	CcSEcCtD
Escitalopram—Dizziness—Epirubicin—pancreatic cancer	6.63e-05	0.000106	CcSEcCtD
Escitalopram—Pruritus—Doxorubicin—pancreatic cancer	6.56e-05	0.000105	CcSEcCtD
Escitalopram—Vomiting—Epirubicin—pancreatic cancer	6.37e-05	0.000102	CcSEcCtD
Escitalopram—Diarrhoea—Doxorubicin—pancreatic cancer	6.35e-05	0.000102	CcSEcCtD
Escitalopram—Rash—Epirubicin—pancreatic cancer	6.32e-05	0.000101	CcSEcCtD
Escitalopram—Dermatitis—Epirubicin—pancreatic cancer	6.32e-05	0.000101	CcSEcCtD
Escitalopram—Headache—Epirubicin—pancreatic cancer	6.28e-05	0.000101	CcSEcCtD
Escitalopram—Dizziness—Doxorubicin—pancreatic cancer	6.13e-05	9.83e-05	CcSEcCtD
Escitalopram—Nausea—Epirubicin—pancreatic cancer	5.95e-05	9.55e-05	CcSEcCtD
Escitalopram—Vomiting—Doxorubicin—pancreatic cancer	5.9e-05	9.45e-05	CcSEcCtD
Escitalopram—Rash—Doxorubicin—pancreatic cancer	5.85e-05	9.38e-05	CcSEcCtD
Escitalopram—Dermatitis—Doxorubicin—pancreatic cancer	5.84e-05	9.37e-05	CcSEcCtD
Escitalopram—Headache—Doxorubicin—pancreatic cancer	5.81e-05	9.32e-05	CcSEcCtD
Escitalopram—Nausea—Doxorubicin—pancreatic cancer	5.51e-05	8.83e-05	CcSEcCtD
Escitalopram—ADRA1A—Signaling Pathways—NOTCH3—pancreatic cancer	3.18e-05	0.000264	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—SLC2A2—pancreatic cancer	3.08e-05	0.000256	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CNR1—pancreatic cancer	3.07e-05	0.000255	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CNR1—pancreatic cancer	3.06e-05	0.000254	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	3.05e-05	0.000253	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—GLP1R—pancreatic cancer	3.04e-05	0.000252	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—PIK3CD—pancreatic cancer	3.02e-05	0.000251	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CNR1—pancreatic cancer	3.01e-05	0.00025	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—DPYD—pancreatic cancer	2.99e-05	0.000248	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—PIK3CG—pancreatic cancer	2.98e-05	0.000247	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—PIK3CG—pancreatic cancer	2.97e-05	0.000246	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—GCG—pancreatic cancer	2.96e-05	0.000246	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—GCG—pancreatic cancer	2.95e-05	0.000245	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	2.94e-05	0.000245	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—PIK3CG—pancreatic cancer	2.92e-05	0.000243	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—GCG—pancreatic cancer	2.91e-05	0.000241	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—PIK3CB—pancreatic cancer	2.9e-05	0.000241	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—PIK3CD—pancreatic cancer	2.88e-05	0.000239	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—PIK3CD—pancreatic cancer	2.87e-05	0.000239	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—SLC2A2—pancreatic cancer	2.83e-05	0.000235	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—PIK3CD—pancreatic cancer	2.83e-05	0.000235	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—AGTR1—pancreatic cancer	2.83e-05	0.000235	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ARG2—pancreatic cancer	2.82e-05	0.000234	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—AGTR1—pancreatic cancer	2.82e-05	0.000234	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—SMAD4—pancreatic cancer	2.81e-05	0.000234	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—CXCL8—pancreatic cancer	2.79e-05	0.000231	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—STK11—pancreatic cancer	2.78e-05	0.000231	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—STK11—pancreatic cancer	2.78e-05	0.000231	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—AGTR1—pancreatic cancer	2.77e-05	0.00023	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—HES1—pancreatic cancer	2.75e-05	0.000228	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—STK11—pancreatic cancer	2.73e-05	0.000227	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	2.68e-05	0.000223	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—PIK3CB—pancreatic cancer	2.63e-05	0.000219	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—PIK3CD—pancreatic cancer	2.62e-05	0.000217	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—PIK3CD—pancreatic cancer	2.61e-05	0.000217	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—PIK3CD—pancreatic cancer	2.57e-05	0.000213	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—CXCL8—pancreatic cancer	2.53e-05	0.00021	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—PIK3CB—pancreatic cancer	2.51e-05	0.000209	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—PIK3CB—pancreatic cancer	2.5e-05	0.000208	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—PIK3CB—pancreatic cancer	2.46e-05	0.000205	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—TYMP—pancreatic cancer	2.46e-05	0.000205	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—SMAD4—pancreatic cancer	2.44e-05	0.000203	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—SMAD4—pancreatic cancer	2.43e-05	0.000202	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—CXCL8—pancreatic cancer	2.41e-05	0.000201	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—TERT—pancreatic cancer	2.41e-05	0.0002	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—CXCL8—pancreatic cancer	2.41e-05	0.0002	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—SMAD4—pancreatic cancer	2.39e-05	0.000199	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—CD44—pancreatic cancer	2.39e-05	0.000198	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—HES1—pancreatic cancer	2.38e-05	0.000198	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—HES1—pancreatic cancer	2.37e-05	0.000197	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—CXCL8—pancreatic cancer	2.37e-05	0.000197	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—HES1—pancreatic cancer	2.34e-05	0.000194	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	2.34e-05	0.000194	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	2.32e-05	0.000192	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—HIF1A—pancreatic cancer	2.3e-05	0.000191	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—TSC2—pancreatic cancer	2.3e-05	0.000191	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—GCG—pancreatic cancer	2.29e-05	0.00019	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—PIK3CB—pancreatic cancer	2.28e-05	0.000189	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—PIK3CB—pancreatic cancer	2.27e-05	0.000189	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—APOE—pancreatic cancer	2.25e-05	0.000187	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—PIK3CB—pancreatic cancer	2.24e-05	0.000186	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—KDR—pancreatic cancer	2.2e-05	0.000183	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CD44—pancreatic cancer	2.2e-05	0.000182	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—CXCL8—pancreatic cancer	2.19e-05	0.000182	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—CXCL8—pancreatic cancer	2.18e-05	0.000181	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—STK11—pancreatic cancer	2.15e-05	0.000179	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—CXCL8—pancreatic cancer	2.15e-05	0.000179	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—GCG—pancreatic cancer	2.1e-05	0.000175	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—NFKBIA—pancreatic cancer	2.1e-05	0.000174	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—TERT—pancreatic cancer	2.09e-05	0.000173	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—TERT—pancreatic cancer	2.08e-05	0.000173	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—NOTCH1—pancreatic cancer	2.07e-05	0.000172	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—TERT—pancreatic cancer	2.05e-05	0.00017	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PIK3CG—pancreatic cancer	2.03e-05	0.000169	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—NRAS—pancreatic cancer	2.03e-05	0.000169	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	2.02e-05	0.000168	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—EGF—pancreatic cancer	2.01e-05	0.000167	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—HIF1A—pancreatic cancer	2e-05	0.000166	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—TSC2—pancreatic cancer	1.99e-05	0.000165	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—HIF1A—pancreatic cancer	1.99e-05	0.000165	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GLP1R—pancreatic cancer	1.98e-05	0.000165	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—TSC2—pancreatic cancer	1.98e-05	0.000165	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—STK11—pancreatic cancer	1.98e-05	0.000164	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—HIF1A—pancreatic cancer	1.96e-05	0.000163	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—TSC2—pancreatic cancer	1.95e-05	0.000162	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—DPYD—pancreatic cancer	1.95e-05	0.000162	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—APOE—pancreatic cancer	1.95e-05	0.000162	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—APOE—pancreatic cancer	1.94e-05	0.000161	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—APOE—pancreatic cancer	1.91e-05	0.000159	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—KDR—pancreatic cancer	1.91e-05	0.000159	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—KDR—pancreatic cancer	1.9e-05	0.000158	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—KDR—pancreatic cancer	1.87e-05	0.000156	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	1.85e-05	0.000154	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—TYMS—pancreatic cancer	1.85e-05	0.000154	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—EGFR—pancreatic cancer	1.85e-05	0.000154	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—NFKBIA—pancreatic cancer	1.82e-05	0.000151	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—NFKBIA—pancreatic cancer	1.81e-05	0.00015	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—NOTCH1—pancreatic cancer	1.8e-05	0.000149	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—NOTCH1—pancreatic cancer	1.79e-05	0.000149	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PIK3CD—pancreatic cancer	1.78e-05	0.000148	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—NFKBIA—pancreatic cancer	1.78e-05	0.000148	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.77e-05	0.000147	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—NOTCH1—pancreatic cancer	1.76e-05	0.000147	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PIK3CG—pancreatic cancer	1.76e-05	0.000146	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—NRAS—pancreatic cancer	1.76e-05	0.000146	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PIK3CG—pancreatic cancer	1.75e-05	0.000146	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—NRAS—pancreatic cancer	1.75e-05	0.000146	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—KRAS—pancreatic cancer	1.75e-05	0.000145	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—EGF—pancreatic cancer	1.74e-05	0.000144	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—EGF—pancreatic cancer	1.73e-05	0.000144	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PIK3CG—pancreatic cancer	1.73e-05	0.000143	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—NRAS—pancreatic cancer	1.73e-05	0.000143	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—EGF—pancreatic cancer	1.71e-05	0.000142	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—TYMS—pancreatic cancer	1.7e-05	0.000141	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—PIK3CA—pancreatic cancer	1.6e-05	0.000133	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—EGFR—pancreatic cancer	1.6e-05	0.000133	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—EGFR—pancreatic cancer	1.6e-05	0.000133	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—EGFR—pancreatic cancer	1.57e-05	0.000131	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PIK3CB—pancreatic cancer	1.55e-05	0.000129	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PIK3CD—pancreatic cancer	1.55e-05	0.000128	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PIK3CD—pancreatic cancer	1.54e-05	0.000128	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.53e-05	0.000127	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.53e-05	0.000127	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PIK3CD—pancreatic cancer	1.52e-05	0.000126	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—KRAS—pancreatic cancer	1.51e-05	0.000126	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—KRAS—pancreatic cancer	1.51e-05	0.000125	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—APOE—pancreatic cancer	1.5e-05	0.000125	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.5e-05	0.000125	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CXCL8—pancreatic cancer	1.49e-05	0.000124	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—KRAS—pancreatic cancer	1.48e-05	0.000123	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—HRAS—pancreatic cancer	1.48e-05	0.000123	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—AKT1—pancreatic cancer	1.44e-05	0.00012	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CD44—pancreatic cancer	1.44e-05	0.000119	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CASP3—pancreatic cancer	1.43e-05	0.000119	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.42e-05	0.000118	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CCND1—pancreatic cancer	1.39e-05	0.000116	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—PIK3CA—pancreatic cancer	1.39e-05	0.000116	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—PIK3CA—pancreatic cancer	1.39e-05	0.000115	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—APOE—pancreatic cancer	1.38e-05	0.000115	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CTNNB1—pancreatic cancer	1.38e-05	0.000115	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GCG—pancreatic cancer	1.38e-05	0.000114	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—PIK3CA—pancreatic cancer	1.36e-05	0.000113	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PIK3CG—pancreatic cancer	1.36e-05	0.000113	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MMP9—pancreatic cancer	1.35e-05	0.000112	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PIK3CB—pancreatic cancer	1.35e-05	0.000112	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PTEN—pancreatic cancer	1.34e-05	0.000112	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PIK3CB—pancreatic cancer	1.34e-05	0.000112	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PIK3CB—pancreatic cancer	1.32e-05	0.00011	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PPARG—pancreatic cancer	1.31e-05	0.000109	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—AKT1—pancreatic cancer	1.31e-05	0.000109	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CXCL8—pancreatic cancer	1.29e-05	0.000108	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—STK11—pancreatic cancer	1.29e-05	0.000107	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CXCL8—pancreatic cancer	1.29e-05	0.000107	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—HRAS—pancreatic cancer	1.29e-05	0.000107	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—HRAS—pancreatic cancer	1.28e-05	0.000107	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CXCL8—pancreatic cancer	1.27e-05	0.000106	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—HRAS—pancreatic cancer	1.26e-05	0.000105	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—AKT1—pancreatic cancer	1.25e-05	0.000104	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	1.25e-05	0.000104	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—AKT1—pancreatic cancer	1.25e-05	0.000104	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—SRC—pancreatic cancer	1.25e-05	0.000104	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CASP3—pancreatic cancer	1.24e-05	0.000103	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CASP3—pancreatic cancer	1.24e-05	0.000103	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—AKT1—pancreatic cancer	1.23e-05	0.000102	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CASP3—pancreatic cancer	1.22e-05	0.000101	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—VEGFA—pancreatic cancer	1.21e-05	0.000101	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CCND1—pancreatic cancer	1.21e-05	0.0001	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PPARG—pancreatic cancer	1.21e-05	0.0001	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CCND1—pancreatic cancer	1.2e-05	9.99e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—STAT3—pancreatic cancer	1.2e-05	9.98e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—NRAS—pancreatic cancer	1.2e-05	9.96e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CTNNB1—pancreatic cancer	1.19e-05	9.92e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PIK3CD—pancreatic cancer	1.19e-05	9.92e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CTNNB1—pancreatic cancer	1.19e-05	9.89e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CCND1—pancreatic cancer	1.18e-05	9.83e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CTNNB1—pancreatic cancer	1.17e-05	9.74e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MMP9—pancreatic cancer	1.17e-05	9.73e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MMP9—pancreatic cancer	1.17e-05	9.7e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PTEN—pancreatic cancer	1.16e-05	9.67e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PTEN—pancreatic cancer	1.16e-05	9.64e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MMP9—pancreatic cancer	1.15e-05	9.55e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PTEN—pancreatic cancer	1.14e-05	9.49e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—AKT1—pancreatic cancer	1.14e-05	9.44e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—AKT1—pancreatic cancer	1.13e-05	9.41e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MYC—pancreatic cancer	1.12e-05	9.28e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—AKT1—pancreatic cancer	1.11e-05	9.26e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—TGFB1—pancreatic cancer	1.11e-05	9.25e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—TYMS—pancreatic cancer	1.11e-05	9.25e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	1.1e-05	9.12e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—EGFR—pancreatic cancer	1.09e-05	9.07e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—SRC—pancreatic cancer	1.08e-05	8.97e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—SRC—pancreatic cancer	1.08e-05	8.94e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—SRC—pancreatic cancer	1.06e-05	8.8e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—VEGFA—pancreatic cancer	1.05e-05	8.74e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—VEGFA—pancreatic cancer	1.05e-05	8.71e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—STAT3—pancreatic cancer	1.04e-05	8.65e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PIK3CB—pancreatic cancer	1.04e-05	8.65e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—NRAS—pancreatic cancer	1.04e-05	8.63e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—STAT3—pancreatic cancer	1.04e-05	8.62e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—NRAS—pancreatic cancer	1.04e-05	8.6e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—VEGFA—pancreatic cancer	1.03e-05	8.57e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—KRAS—pancreatic cancer	1.03e-05	8.57e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PTGS2—pancreatic cancer	1.03e-05	8.57e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—STAT3—pancreatic cancer	1.02e-05	8.49e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—NRAS—pancreatic cancer	1.02e-05	8.47e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MYC—pancreatic cancer	9.67e-06	8.04e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—TGFB1—pancreatic cancer	9.65e-06	8.02e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MYC—pancreatic cancer	9.64e-06	8.01e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—TGFB1—pancreatic cancer	9.62e-06	7.99e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	9.57e-06	7.95e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MYC—pancreatic cancer	9.49e-06	7.89e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PTGS2—pancreatic cancer	9.48e-06	7.88e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PIK3CA—pancreatic cancer	9.48e-06	7.87e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—TGFB1—pancreatic cancer	9.47e-06	7.87e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—EGFR—pancreatic cancer	9.46e-06	7.86e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—EGFR—pancreatic cancer	9.43e-06	7.84e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—EGFR—pancreatic cancer	9.29e-06	7.71e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—TP53—pancreatic cancer	9.17e-06	7.62e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—APOE—pancreatic cancer	9.05e-06	7.52e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PTEN—pancreatic cancer	8.99e-06	7.47e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—KRAS—pancreatic cancer	8.94e-06	7.43e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—KRAS—pancreatic cancer	8.91e-06	7.4e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—KRAS—pancreatic cancer	8.77e-06	7.29e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—HRAS—pancreatic cancer	8.77e-06	7.29e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PTEN—pancreatic cancer	8.27e-06	6.87e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PIK3CA—pancreatic cancer	8.21e-06	6.82e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PIK3CA—pancreatic cancer	8.19e-06	6.8e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	8.17e-06	6.79e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PIK3CA—pancreatic cancer	8.06e-06	6.7e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—TP53—pancreatic cancer	7.94e-06	6.6e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—TP53—pancreatic cancer	7.92e-06	6.58e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PPARG—pancreatic cancer	7.88e-06	6.55e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—TP53—pancreatic cancer	7.8e-06	6.48e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—AKT1—pancreatic cancer	7.74e-06	6.43e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—HRAS—pancreatic cancer	7.6e-06	6.31e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—HRAS—pancreatic cancer	7.57e-06	6.29e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—HRAS—pancreatic cancer	7.46e-06	6.19e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	7.18e-06	5.97e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—AKT1—pancreatic cancer	6.71e-06	5.57e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—AKT1—pancreatic cancer	6.69e-06	5.56e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—AKT1—pancreatic cancer	6.58e-06	5.47e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PIK3CA—pancreatic cancer	6.34e-06	5.27e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	6.26e-06	5.2e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PTGS2—pancreatic cancer	6.2e-06	5.15e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	5.84e-06	4.85e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PTEN—pancreatic cancer	5.41e-06	4.49e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—AKT1—pancreatic cancer	5.18e-06	4.31e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—AKT1—pancreatic cancer	4.77e-06	3.96e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	3.82e-06	3.17e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—AKT1—pancreatic cancer	3.12e-06	2.59e-05	CbGpPWpGaD
